ASC Therapeutics

ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc. The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2022 focusing on several blood disorders. We are dedicated to discovering, developing and delivering cures for intractable and rare diseases. We are passionate about helping patients lead more hopeful, healthier and happier lives.